Can the Indian targeted drug Mobosetinib/Mobosetinib be effective?

Mobocertinib/Mobocertinib (Mobocertinib) is a targeted therapy drug for patients with non-small cell lung cancer who have EGFR gene mutations. The drug has been approved in some countries and regions, and clinical trial results have shown its efficacy in some patients. It is understood that there are no original or generic drugs of mobosetinib produced in India and other regions.

Whether moboxetinib can be effective depends on the patient's specific situation. Different patients have different conditions and respond differently to medications. In addition, the efficacy and safety of moboxetinib are also related to the patient's physical condition, age, gender, race, eating habits, lifestyle and other factors. Before using mobosertinib, patients are advised to have a detailed discussion and evaluation with their doctor to understand whether the drug is suitable for their condition, as well as its possible efficacy and risks. At the same time, during the treatment with mobosetinib, patients should closely cooperate with the doctor's treatment recommendations, take the medicine on time according to the doctor's instructions, pay attention to observe the body's reaction, and promptly report any discomfort or abnormal reactions.

Mobosetinib The original drug has been launched in China, but it is not included in the medical insurance. The price of the common specification 40mg*112 pills per box is about 40,000 yuan, which is very high. The Hong Kong clinical version specification 40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.